Screener
Crinetics Pharmaceuticals CRNX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Crinetics Pharmaceuticals’s reported figures.
Based on the most recent quarter.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
FAQ
- What is Crinetics Pharmaceuticals's debt-to-equity?
- Crinetics Pharmaceuticals (CRNX) reported debt-to-equity of 0× in Q1 2026.
- How has Crinetics Pharmaceuticals's debt-to-equity changed year-over-year?
- Crinetics Pharmaceuticals's debt-to-equity decreased by 7.7% year-over-year, from 0× to 0×.
- What is the long-term trend for Crinetics Pharmaceuticals's debt-to-equity?
- Over 5 years (2020 to 2025), Crinetics Pharmaceuticals's debt-to-equity has grown at a 11.2% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Crinetics Pharmaceuticals's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude